DNA修復薬市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年から2031年

DNA修復薬市場- レポートの範囲

世界のDNA修復薬市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、2023年を基準年、2031年を予測年とし、2017年から2031年までの世界市場の収益を提供します。また、2023年から2031年までの世界市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、DNA修復薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界のDNA修復薬市場の競合情勢を詳しく掘り下げています。世界のDNA修復薬市場で活動している主要プレーヤーが特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のDNA修復薬市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

• イントロダクション
• 概要
• 市場力学
• 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

• 技術の進歩
• 主要国の世界の病気の有病率と罹患率
• パイプライン分析
• 地域/世界ごとの規制シナリオ
• COVID-19感染症パンデミックによる業界への影響（バリューチェーンと短期・中期・長期的な影響）

第6章 世界市場の分析と予測：医薬品タイプ別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：医薬品タイプ別、2017-2031
  • PARP阻害剤
  • アルキル化剤
  • その他
• 市場魅力分析：医薬品タイプ別

第7章 世界市場の分析と予測：剤形別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：剤形別、2017-2031
  • 乳がん
  • 卵巣がん
  • 肺がん
  • 頭頸部がん
  • その他
• 市場魅力分析：剤形別

第8章 世界市場の分析と予測：剤形別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：剤形別、2017-2031
  • 錠剤
  • カプセル
  • 注射剤
• 市場魅力分析：剤形別

第9章 世界市場の分析と予測：流通チャネル別

• イントロダクションと定義
• 主な調査結果/発展
• 市場金額予測：流通チャネル別、2017-2031
  • 小売薬局
  • 病院薬局
  • オンライン薬局
• 市場魅力度分析：流通チャネル別

第10章 世界市場の分析と予測：地域別

• 主な調査結果
• 市場金額予測：地域別、2017-2031
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ
• 国・地域別の市場魅力度

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東およびアフリカ市場の分析と予測

第16章 競合情勢

• 市場企業-競合マトリックス（企業の階層および規模別）
• 市場シェア分析：企業別（2021年）
• 企業プロファイル
  • AstraZeneca plc
  • Clovis Oncology
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Merck &Co. Inc.
  • Novartis AG
  • Johnson &Johnson
  • Bristol Myers Squibb Company
  • Onxeo

List of Tables

• Table 01: Global DNA Repair Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 01: Global DNA Repair Drugs Market Value (US$ Mn) Forecast, by Application, 2017-2031
• Table 02: Global DNA Repair Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
• Table 03: Global DNA Repair Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 04: Global DNA Repair Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
• Table 05: North America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
• Table 06: North America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 01: North America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Application, 2017-2031
• Table 07: North America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
• Table 08: North America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 09: Europe DNA Repair Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 10: Europe DNA Repair Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 11: Europe DNA Repair Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
• Table 01: Europe DNA Repair Drugs Market Value (US$ Mn) Forecast, by Application, 2017-2031
• Table 12: Europe DNA Repair Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 13: Asia Pacific DNA Repair Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 14: Asia Pacific DNA Repair Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 15: Asia Pacific DNA Repair Drugs Market Value (US$ Mn) Forecast, by Application, 2017-2031
• Table 11: Asia Pacific DNA Repair Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
• Table 16: Asia Pacific DNA Repair Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 17: Latin America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 18: Latin America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 15: Latin America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Application, 2017-2031
• Table 19: Latin America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
• Table 20: Latin America DNA Repair Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
• Table 21: Middle East & Africa DNA Repair Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 22: Middle East & Africa DNA Repair Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
• Table 15: Middle East & Africa DNA Repair Drugs Market Value (US$ Mn) Forecast, by Application, 2017-2031
• Table 23: Middle East & Africa DNA Repair Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
• Table 24: Middle East & Africa DNA Repair Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

• Figure 01: Global DNA Repair Drugs Market Value (US$ Mn) Forecast, 2017-2031
• Figure 02: Global DNA Repair Drugs Market Value Share, by Drug Type, 2022
• Figure 03: Global DNA Repair Drugs Market Value Share, by Dosage Form, 2022
• Figure 04: Global DNA Repair Drugs Market Value Share, by Distribution Channel, 2022
• Figure 05: Global DNA Repair Drugs Market Value Share, by Region, 2022
• Figure 06: Global DNA Repair Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
• Figure 07: Global DNA Repair Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
• Figure 08: Global DNA Repair Drugs Market Revenue (US$ Mn), by PARP Inhibitors, 2017-2031
• Figure 09: Global DNA Repair Drugs Market Revenue (US$ Mn), by Alkylating Agents, 2017-2031
• Figure 10: Global DNA Repair Drugs Market Revenue (US$ Mn), by Others, 2017-2031
• Figure 11: Global DNA Repair Drugs Market Revenue (US$ Mn), by Others, 2017-2031
• Figure 06: Global DNA Repair Drugs Market Value Share Analysis, by Application, 2022 and 2031
• Figure 07: Global DNA Repair Drugs Market Attractiveness Analysis, by Application, 2023-2031
• Figure 08: Global DNA Repair Drugs Market Revenue (US$ Mn), by Breast Cancer, 2017-2031
• Figure 09: Global DNA Repair Drugs Market Revenue (US$ Mn), by Ovarian Cancer, 2017-2031
• Figure 08: Global DNA Repair Drugs Market Revenue (US$ Mn), by Breast Cancer, 2017-2031
• Figure 09: Global DNA Repair Drugs Market Revenue (US$ Mn), by Lung Cancer, 2017-2031
• Figure 08: Global DNA Repair Drugs Market Revenue (US$ Mn), by Head and Neck Cancer, 2017-2031
• Figure 09: Global DNA Repair Drugs Market Revenue (US$ Mn), by Others, 2017-2031
• Figure 16: Global DNA Repair Drugs Market Value Share Analysis, by Dosage Form, 2017-2031
• Figure 17: Global DNA Repair Drugs Market Attractiveness Analysis, by Dosage Form, 2023-2031
• Figure 18: Global DNA Repair Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 19: Global DNA Repair Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
• Figure 20: Global DNA Repair Drugs Market Value Share Analysis, by Region, 2022 and 2031
• Figure 21: Global DNA Repair Drugs Market Attractiveness Analysis, by Region, 2023-2031
• Figure 22: North America DNA Repair Drugs Market Value (US$ Mn) Forecast, 2017-2031
• Figure 23: North America DNA Repair Drugs Market Value Share Analysis, by Country, 2022 and 2031
• Figure 24: North America DNA Repair Drugs Market Attractiveness Analysis, by Country, 2023-2031
• Figure 25: North America DNA Repair Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
• Figure 26: North America DNA Repair Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
• Figure 27: North America DNA Repair Drugs Market Value Share Analysis (US$ Mn), by Dosage Form, 2017-2031
• Figure 28: North America DNA Repair Drugs Market Attractiveness Analysis, by Dosage Form, 2023-2031
• Figure 29: North America DNA Repair Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 30: North America DNA Repair Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
• Figure 31: Europe DNA Repair Drugs Market Value (US$ Mn) Forecast, 2017-2031
• Figure 32: Europe DNA Repair Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
• Figure 33: Europe DNA Repair Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
• Figure 34: Europe DNA Repair Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
• Figure 35: Europe DNA Repair Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
• Figure 36: Europe DNA Repair Drugs Market Value Share Analysis, by Dosage Form, 2017-2031
• Figure 37: Europe DNA Repair Drugs Market Attractiveness Analysis, by Dosage Form, 2023-2031
• Figure 38: Europe DNA Repair Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 39: Europe DNA Repair Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
• Figure 40: Asia Pacific DNA Repair Drugs Market Value (US$ Mn) Forecast, 2017-2031
• Figure 41: Asia Pacific DNA Repair Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
• Figure 42: Asia Pacific DNA Repair Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
• Figure 43: Asia Pacific DNA Repair Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
• Figure 44: Asia Pacific DNA Repair Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
• Figure 45: Asia Pacific DNA Repair Drugs Market Value Share Analysis, by Dosage Form, 2017-2031
• Figure 46: Asia Pacific DNA Repair Drugs Market Attractiveness Analysis, by Dosage Form, 2023-2031
• Figure 47: Asia Pacific DNA Repair Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 48: Asia Pacific DNA Repair Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
• Figure 49: Latin America DNA Repair Drugs Market Value (US$ Mn) Forecast, 2017-2031
• Figure 50: Latin America DNA Repair Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
• Figure 51: Latin America DNA Repair Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
• Figure 52: Latin America DNA Repair Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
• Figure 53: Latin America DNA Repair Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
• Figure 54: Latin America DNA Repair Drugs Market Value Share Analysis, by Dosage Form, 2017-2031
• Figure 55: Latin America DNA Repair Drugs Market Attractiveness Analysis, by Dosage Form, 2023-2031
• Figure 56: Latin America DNA Repair Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 57: Latin America DNA Repair Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
• Figure 58: Middle East & Africa DNA Repair Drugs Market Value (US$ Mn) Forecast, 2017-2031
• Figure 59: Middle East & Africa DNA Repair Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
• Figure 60: Middle East & Africa DNA Repair Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
• Figure 61: Middle East & Africa DNA Repair Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
• Figure 62: Middle East & Africa DNA Repair Drugs Market Attractiveness Analysis, by Drug Type, 2023-2031
• Figure 63: Middle East & Africa DNA Repair Drugs Market Value Share Analysis, by Dosage Form, 2017-2031
• Figure 64: Middle East & Africa DNA Repair Drugs Market Attractiveness Analysis, by Dosage Form, 2023-2031
• Figure 65: Middle East & Africa DNA Repair Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
• Figure 66: Middle East & Africa DNA Repair Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031

DNA Repair Drugs Market - Scope of Report

TMR's report on the global DNA Repair Drugs Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global DNA Repair Drugs Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global DNA Repair Drugs Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the DNA Repair Drugs Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global DNA Repair Drugs Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global DNA Repair Drugs Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global DNA Repair Drugs Market.

The report delves into the competitive landscape of the global DNA Repair Drugs Market. Key players operating in the global DNA Repair Drugs Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global DNA Repair Drugs Market profiled in this report.

Key Questions Answered in Global DNA Repair Drugs Market Report:

• What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
• What are the opportunities in the global DNA Repair Drugs Market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

DNA Repair Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global DNA Repair Drugs Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global DNA Repair Drugs Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global DNA Repair Drugs.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global DNA Repair Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global DNA Repair Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Technological Advancements
• 5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
• 5.3. Pipeline Analysis
• 5.4. Regulatory Scenario by Region/Globally
• 5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global DNA Repair Drugs Market Analysis and Forecast, by Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Drug Type, 2017-2031
  • 6.3.1. PARP Inhibitors
  • 6.3.2. Alkylating Agents
  • 6.3.3. Others
• 6.4. Market Attractiveness Analysis, by Drug Type

7. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 7.3.1. Breast Cancer
  • 7.3.2. Ovarian Cancer
  • 7.3.3. Lung Cancer
  • 7.3.4. Head and Neck Cancer
  • 7.3.5. Others
• 7.4. Market Attractiveness Analysis, by Dosage Form

8. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 8.3.1. Tablets
  • 8.3.2. Capsules
  • 8.3.3. Injectables
• 8.4. Market Attractiveness Analysis, by Dosage Form

9. Global DNA Repair Drugs Market Analysis and Forecast, by Distribution Channel

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 9.3.1. Retail Pharmacies
  • 9.3.2. Hospital Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global DNA Repair Drugs Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2017-2031
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Country/Region

11. North America DNA Repair Drugs Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Drug Type, 2017-2031
  • 11.2.1. PARP Inhibitors
  • 11.2.2. Alkylating Agents
  • 11.2.3. Others
• 11.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 11.3.1. Breast Cancer
  • 11.3.2. Ovarian Cancer
  • 11.3.3. Lung Cancer
  • 11.3.4. Head and Neck Cancer
  • 11.3.5. Others
• 11.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 11.4.1. Tablets
  • 11.4.2. Capsules
  • 11.4.3. Injectables
• 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.5.1. Retail Pharmacies
  • 11.5.2. Hospital Pharmacies
  • 11.5.3. Online Pharmacies
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Drug Type
  • 11.7.2. By Dosage Form
  • 11.7.3. By Dosage Form
  • 11.7.4. By Distribution Channel
  • 11.7.5. By Country/Sub-region

12. Europe DNA Repair Drugs Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Drug Type, 2017-2031
  • 12.2.1. PARP Inhibitors
  • 12.2.2. Alkylating Agents
  • 12.2.3. Others
• 12.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 12.3.1. Breast Cancer
  • 12.3.2. Ovarian Cancer
  • 12.3.3. Lung Cancer
  • 12.3.4. Head and Neck Cancer
  • 12.3.5. Others
• 12.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 12.4.1. Tablets
  • 12.4.2. Capsules
  • 12.4.3. Injectables
• 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.5.1. Retail Pharmacies
  • 12.5.2. Hospital Pharmacies
  • 12.5.3. Online Pharmacies
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Drug Type
  • 12.7.2. By Dosage Form
  • 12.7.3. By Dosage Form
  • 12.7.4. By Distribution Channel
  • 12.7.5. By Country/Sub-region

13. Asia Pacific DNA Repair Drugs Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Drug Type, 2017-2031
  • 13.2.1. PARP Inhibitors
  • 13.2.2. Alkylating Agents
  • 13.2.3. Others
• 13.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 13.3.1. Breast Cancer
  • 13.3.2. Ovarian Cancer
  • 13.3.3. Lung Cancer
  • 13.3.4. Head and Neck Cancer
  • 13.3.5. Others
• 13.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 13.4.1. Tablets
  • 13.4.2. Capsules
  • 13.4.3. Injectables
• 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.5.1. Retail Pharmacies
  • 13.5.2. Hospital Pharmacies
  • 13.5.3. Online Pharmacies
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Drug Type
  • 13.7.2. By Dosage Form
  • 13.7.3. By Dosage Form
  • 13.7.4. By Distribution Channel
  • 13.7.5. By Country/Sub-region

14. Latin America DNA Repair Drugs Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Drug Type, 2017-2031
  • 14.2.1. PARP Inhibitors
  • 14.2.2. Alkylating Agents
  • 14.2.3. Others
• 14.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 14.3.1. Breast Cancer
  • 14.3.2. Ovarian Cancer
  • 14.3.3. Lung Cancer
  • 14.3.4. Head and Neck Cancer
  • 14.3.5. Others
• 14.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 14.4.1. Tablets
  • 14.4.2. Capsules
  • 14.4.3. Injectables
• 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 14.5.1. Retail Pharmacies
  • 14.5.2. Hospital Pharmacies
  • 14.5.3. Online Pharmacies
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Drug Type
  • 14.7.2. By Dosage Form
  • 14.7.3. By Dosage Form
  • 14.7.4. By Distribution Channel
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa DNA Repair Drugs Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Drug Type, 2017-2031
  • 15.2.1. PARP Inhibitors
  • 15.2.2. Alkylating Agents
  • 15.2.3. Others
• 15.3. Market Value Forecast, by Dosage Form, 2017-2031
  • 15.3.1. Breast Cancer
  • 15.3.2. Ovarian Cancer
  • 15.3.3. Lung Cancer
  • 15.3.4. Head and Neck Cancer
  • 15.3.5. Others
• 15.4. Market Value Forecast, by Dosage Form, 2017-2031
  • 15.4.1. Tablets
  • 15.4.2. Capsules
  • 15.4.3. Injectables
• 15.5. Market Value Forecast, by Distribution Channel, 2017-2031
  • 15.5.1. Retail Pharmacies
  • 15.5.2. Hospital Pharmacies
  • 15.5.3. Online Pharmacies
• 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Drug Type
  • 15.7.2. By Dosage Form
  • 15.7.3. By Application
  • 15.7.4. By Distribution Channel
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2021)
• 16.3. Company Profiles
  • 16.3.1. AstraZeneca plc
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Product Portfolio
    • 16.3.1.3. Financial Overview
    • 16.3.1.4. SWOT Analysis
    • 16.3.1.5. Strategic Overview
  • 16.3.2. Clovis Oncology
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Product Portfolio
    • 16.3.2.3. Financial Overview
    • 16.3.2.4. SWOT Analysis
    • 16.3.2.5. Strategic Overview
  • 16.3.3. GlaxoSmithKline plc
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Product Portfolio
    • 16.3.3.3. Financial Overview
    • 16.3.3.4. SWOT Analysis
    • 16.3.3.5. Strategic Overview
  • 16.3.4. Pfizer Inc.
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Product Portfolio
    • 16.3.4.3. Financial Overview
    • 16.3.4.4. SWOT Analysis
    • 16.3.4.5. Strategic Overview
  • 16.3.5. Merck & Co. Inc.
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Product Portfolio
    • 16.3.5.3. Financial Overview
    • 16.3.5.4. SWOT Analysis
    • 16.3.5.5. Strategic Overview
  • 16.3.6. Novartis AG
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Product Portfolio
    • 16.3.6.3. Financial Overview
    • 16.3.6.4. SWOT Analysis
    • 16.3.6.5. Strategic Overview
  • 16.3.7. Johnson & Johnson
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Product Portfolio
    • 16.3.7.3. Financial Overview
    • 16.3.7.4. SWOT Analysis
    • 16.3.7.5. Strategic Overview
  • 16.3.8. Bristol Myers Squibb Company
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Product Portfolio
    • 16.3.8.3. Financial Overview
    • 16.3.8.4. SWOT Analysis
    • 16.3.8.5. Strategic Overview
  • 16.3.9. Onxeo
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Product Portfolio
    • 16.3.9.3. Financial Overview
    • 16.3.9.4. SWOT Analysis
    • 16.3.9.5. Strategic Overview